Literature DB >> 30687624

Paradigm shift in the local treatment of breast cancer: mastectomy to breast conservation surgery.

Kowsi Murugappan1,2, Apoorva Saboo1, Lu Kuo2, Owen Ung1,2.   

Abstract

There have been fundamental changes in the approach to breast cancer management over the last century but the primary objective of achieving oncological safety remains unchanged. This evolution is highlighted with a summary of the key evidences in support of the oncological safety of breast conserving surgery (BCS) in early breast cancer (EBC) management. We will also discuss the increasingly pivotal role that neoadjuvant chemotherapy (NACT) may play, in the local treatment of EBC and locally advanced breast cancer (LABC) and the long-term surgical and oncological outcomes.

Entities:  

Keywords:  Mastectomy; breast conservation surgery (BCS); neoadjuvant chemotherapy (NACT); oncological safety

Year:  2018        PMID: 30687624      PMCID: PMC6323252          DOI: 10.21037/gs.2018.09.01

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  89 in total

1.  Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy.

Authors:  L Assersohn; T J Powles; S Ashley; A G Nash; A J Neal; N Sacks; J Chang; U Querci della Rovere; N Naziri
Journal:  Ann Oncol       Date:  1999-12       Impact factor: 32.976

2.  The role of reduction mammaplasty in reconstructing partial mastectomy defects.

Authors:  Albert Losken; Eric T Elwood; Toncred M Styblo; John Bostwick
Journal:  Plast Reconstr Surg       Date:  2002-03       Impact factor: 4.730

3.  Experience with reduction mammaplasty combined with breast conservation therapy in the treatment of breast cancer.

Authors:  Scott L Spear; Christopher V Pelletiere; Andrew J Wolfe; Theodore N Tsangaris; Marie F Pennanen
Journal:  Plast Reconstr Surg       Date:  2003-03       Impact factor: 4.730

4.  Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction.

Authors:  S K Al-Ghazal; L Fallowfield; R W Blamey
Journal:  Eur J Cancer       Date:  2000-10       Impact factor: 9.162

5.  The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups.

Authors:  C Vrieling; L Collette; A Fourquet; W J Hoogenraad; J H Horiot; J J Jager; M Pierart; P M Poortmans; H Struikmans; B Maat; E Van Limbergen; H Bartelink
Journal:  Radiother Oncol       Date:  2000-06       Impact factor: 6.280

6.  Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

Authors:  J A van der Hage; C J van de Velde; J P Julien; M Tubiana-Hulin; C Vandervelden; L Duchateau
Journal:  J Clin Oncol       Date:  2001-11-15       Impact factor: 44.544

7.  MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer.

Authors:  Laura Liberman; Elizabeth A Morris; D David Dershaw; Andrea F Abramson; Lee K Tan
Journal:  AJR Am J Roentgenol       Date:  2003-04       Impact factor: 3.959

8.  Oncoplastic techniques allow extensive resections for breast-conserving therapy of breast carcinomas.

Authors:  Krishna B Clough; Jacqueline S Lewis; Benoit Couturaud; Alfred Fitoussi; Claude Nos; Marie-Christine Falcou
Journal:  Ann Surg       Date:  2003-01       Impact factor: 12.969

9.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

Authors:  Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

10.  Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.

Authors:  Umberto Veronesi; Natale Cascinelli; Luigi Mariani; Marco Greco; Roberto Saccozzi; Alberto Luini; Marisel Aguilar; Ettore Marubini
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

View more
  6 in total

1.  Modified radical mastectomy for anterior thoracic nerve and intercostobrachial nerve protection (case report).

Authors:  Shengchao Huang; Pu Qiu; Weizhang Chen; Yuanqi Zhang; Kangwei Luo; Jianwen Li
Journal:  Gland Surg       Date:  2020-04

Review 2.  Prospect of exosomal circular RNAs in breast Cancer: presents and future.

Authors:  Elham Zokaei; Farzaneh Darbeheshti; Nima Rezaei
Journal:  Mol Biol Rep       Date:  2022-05-09       Impact factor: 2.742

3.  Usefulness of postoperative serum translocator protein as a predictive marker for delirium after breast cancer surgery in elderly women.

Authors:  Guo-Wen Lu; Yi-Er Chou; Wan-Ling Jin; Xiao-Bao Su
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

4.  Effect of pathologic stages on postmastectomy radiation therapy in breast cancer receiving neoadjuvant chemotherapy and total mastectomy: A Cancer Database Analysis.

Authors:  Jiaqiang Zhang; Chang-Yun Lu; Chien-Hsin Chen; Ho-Min Chen; Szu-Yuan Wu
Journal:  Breast       Date:  2020-09-07       Impact factor: 4.380

Review 5.  Breast conservation surgery & oncoplasty in India - Current scenario.

Authors:  Vani Parmar; Chaitanyanand B Koppiker; Santosh Dixit
Journal:  Indian J Med Res       Date:  2021-08       Impact factor: 5.274

6.  Comparison of breast cancer patients who underwent partial mastectomy (PM) with mini latissimus dorsi flap (MLDF) and subcutaneous mastectomy with implant (M + I) regarding quality of life (QOL), cosmetic outcome and survival rates.

Authors:  Vahit Ozmen; Serkan Ilgun; Burcu Celet Ozden; Alper Ozturk; Fatma Aktepe; Filiz Agacayak; Filiz Elbuken; Gul Alco; Cetin Ordu; Zeynep Erdogan Iyigun; Hocaoglu Emre; Kezban Pilancı; Gursel Soybir; Tolga Ozmen
Journal:  World J Surg Oncol       Date:  2020-05-05       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.